151 related articles for article (PubMed ID: 19347722)
1. The emerging role of bendamustine in follicular lymphoma.
Friedberg JW
Leuk Lymphoma; 2009 Mar; 50(3):317-8. PubMed ID: 19347722
[No Abstract] [Full Text] [Related]
2. HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine.
Tsutsumi Y; Ogasawara R; Miyashita N; Tanaka J; Asaka M; Imamura M
Int J Hematol; 2012 May; 95(5):588-91. PubMed ID: 22419099
[No Abstract] [Full Text] [Related]
3. Paraneoplastic pemphigus occurring after bendamustine and rituximab therapy for relapsed follicular lymphoma.
Higo T; Miyagaki T; Nakamura F; Shinohara A; Asano H; Abe H; Senda N; Yoshizaki A; Fukayama M; Kurokawa M
Ann Hematol; 2015 Apr; 94(4):683-5. PubMed ID: 25199505
[No Abstract] [Full Text] [Related]
4. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
[TBL] [Abstract][Full Text] [Related]
5. Resolution of granuloma annulare following treatment with bendamustine and rituximab in a patient with follicular lymphoma: a serendipitous finding.
Shah BK; Hewett Y; Peterson A; Tretheway D
J Postgrad Med; 2014; 60(4):406-8. PubMed ID: 25370553
[TBL] [Abstract][Full Text] [Related]
6. The optimal management of follicular lymphoma: an evolving field.
Ujjani C; Cheson BD
Drugs; 2013 Sep; 73(13):1395-403. PubMed ID: 23884816
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.
Hess G; Keller U; Scholz CW; Witzens-Harig M; Atta J; Buske C; Kirschey S; Ruckes C; Medler C; van Oordt C; Klapper W; Theobald M; Dreyling M
Leukemia; 2015 Aug; 29(8):1695-701. PubMed ID: 25765545
[TBL] [Abstract][Full Text] [Related]
8. Bendamustine in chronic lymphocytic leukemia: the future is combination therapy.
Friedberg JW
Leuk Lymphoma; 2009 Sep; 50(9):1399-400. PubMed ID: 19811324
[No Abstract] [Full Text] [Related]
9. [II. Treatment trend and outlook on bendamustine for mantle cell lymphoma and follicular lymphoma].
Ogura M
Gan To Kagaku Ryoho; 2012 May; 39(5):736-42. PubMed ID: 22701900
[No Abstract] [Full Text] [Related]
10. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
Fowler N; Kahl BS; Lee P; Matous JV; Cashen AF; Jacobs SA; Letzer J; Amin B; Williams ME; Smith S; Saleh A; Rosen P; Shi H; Parasuraman S; Cheson BD
J Clin Oncol; 2011 Sep; 29(25):3389-95. PubMed ID: 21810687
[TBL] [Abstract][Full Text] [Related]
11. [Recent therapeutic strategy for follicular lymphoma].
Ogura M
Nihon Naika Gakkai Zasshi; 2007 Apr; 96(4):787-804. PubMed ID: 17506321
[No Abstract] [Full Text] [Related]
12. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
[TBL] [Abstract][Full Text] [Related]
13. Follicular lymphoma.
Ghielmini M
Ann Oncol; 2010 Oct; 21 Suppl 7():vii151-3. PubMed ID: 20943608
[TBL] [Abstract][Full Text] [Related]
14. Infections associated with bendamustine and anti-CD20 antibody in untreated follicular lymphoma: a real-world study.
Saburi M; Okuhiro K; Yoshida N; Haruyama T; Moroga Y; Yanai Y; Itani K; Takano K; Honda S; Ono K; Iwanaga M; Sasaki H; Abe M; Kohno K; Nakayama T; Ohtsuka E; Ogata M
J Clin Exp Hematop; 2023 Sep; 63(3):197-200. PubMed ID: 37518273
[No Abstract] [Full Text] [Related]
15. In vitro studies with bendamustine: enhanced activity in combination with rituximab.
Rummel MJ; Chow KU; Hoelzer D; Mitrou PS; Weidmann E
Semin Oncol; 2002 Aug; 29(4 Suppl 13):12-4. PubMed ID: 12170426
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine and rituximab for indolent B-cell non-hodgkin lymphoma in patients with compensated hepatitis C cirrhosis: a case series.
Parker SM; Hyder MA; Fesler MJ
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):e15-7. PubMed ID: 24060287
[No Abstract] [Full Text] [Related]
17. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma.
Carter SJ; Bernstein SH; Friedberg JW; Barr PM
Leuk Res; 2011 Nov; 35(11):e223-4. PubMed ID: 21824654
[No Abstract] [Full Text] [Related]
18. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.
Walter E; Schmitt T; Dietrich S; Ho A; Witzens-Harig M
Leuk Lymphoma; 2012 Nov; 53(11):2290-2. PubMed ID: 22475324
[No Abstract] [Full Text] [Related]
19. [Recommendation for the optimal use of bendamustine in Japan].
Ohmachi K; Maruyama D; Nisikori M; Suzuki T; Izutsu K
Rinsho Ketsueki; 2014 Mar; 55(3):311-20. PubMed ID: 24681934
[No Abstract] [Full Text] [Related]
20. Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
Cheson BD
Clin Adv Hematol Oncol; 2008 Sep; 6(9):4-6. PubMed ID: 18998258
[No Abstract] [Full Text] [Related]
[Next] [New Search]
